Gilead Sciences annual operating income
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gilead Sciences Operating Income Growth & History (GILD)
Gilead Sciences's operating income was $10.02B for fiscal 2025.
View full Gilead Sciences company overviewGilead Sciences annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $10.02B | $8.36B | +503.01% |
| 2024 | 2024-12-31 | $1.66B | −$5.94B | −78.15% |
| 2023 | 2023-12-31 | $7.61B | $275.0M | +3.75% |
| 2022 | 2022-12-31 | $7.33B | −$2.59B | −26.09% |
| 2021 | 2021-12-31 | $9.92B | $5.85B | +143.63% |
| 2020 | 2020-12-31 | $4.07B | −$216.0M | −5.04% |
| 2019 | 2019-12-31 | $4.29B | −$3.91B | −47.72% |
| 2018 | 2018-12-31 | $8.20B | −$5.92B | −41.94% |
| 2017 | 2017-12-31 | $14.12B | −$3.51B | −19.90% |
| 2016 | 2016-12-31 | $17.63B | −$4.56B | −20.55% |
| 2015 | 2015-12-31 | $22.19B | $6.93B | +45.38% |
| 2014 | 2014-12-31 | $15.27B | $10.74B | +237.42% |
| 2013 | 2013-12-31 | $4.52B | $514.0M | +12.82% |
| 2012 | 2012-12-31 | $4.01B | $220.2M | +5.81% |
| 2011 | 2011-12-31 | $3.79B | −$172.4M | −4.35% |
| 2010 | 2010-12-31 | $3.96B | $433.0M | +12.27% |
| 2009 | 2009-12-31 | $3.53B | $850.7M | +31.76% |
| 2008 | 2008-12-31 | $2.68B | $514.0M | +23.75% |
| 2007 | 2007-12-31 | $2.16B | — | — |
Gilead Sciences quarterly operating income
Q2.08
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$10.39B | −$12.87B | — |
| Q1 2026 | 2026-03-31 | $2.59B | $349.0M | +15.60% |
| Q4 2025 | 2025-12-31 | $1.98B | −$468.0M | −19.09% |
| Q3 2025 | 2025-09-30 | $3.33B | $2.44B | +274.66% |
| Q2 2025 | 2025-06-30 | $2.47B | −$170.0M | −6.43% |
| Q1 2025 | 2025-03-31 | $2.24B | $6.56B | — |
| Q4 2024 | 2024-12-31 | $2.45B | $840.0M | +52.11% |
| Q3 2024 | 2024-09-30 | $888.0M | −$1.74B | −66.15% |
| Q2 2024 | 2024-06-30 | $2.64B | $979.0M | +58.80% |
| Q1 2024 | 2024-03-31 | −$4.32B | −$6.03B | — |
| Q4 2023 | 2023-12-31 | $1.61B | −$655.0M | −28.89% |
| Q3 2023 | 2023-09-30 | $2.62B | −$214.0M | −7.54% |
| Q2 2023 | 2023-06-30 | $1.67B | −$364.0M | −17.94% |
| Q1 2023 | 2023-03-31 | $1.71B | $1.51B | +765.48% |
| Q4 2022 | 2022-12-31 | $2.27B | $1.33B | +141.17% |
| Q3 2022 | 2022-09-30 | $2.84B | −$1.00B | −26.16% |
| Q2 2022 | 2022-06-30 | $2.03B | −$217.0M | −9.66% |
| Q1 2022 | 2022-03-31 | $197.0M | −$2.69B | −93.18% |
| Q4 2021 | 2021-12-31 | $940.0M | −$1.71B | −64.54% |
| Q3 2021 | 2021-09-30 | $3.84B | $1.84B | +92.00% |
| Q2 2021 | 2021-06-30 | $2.25B | $5.23B | — |
| Q1 2021 | 2021-03-31 | $2.89B | $488.0M | +20.32% |
| Q4 2020 | 2020-12-31 | $2.65B | $1.56B | +142.54% |
| Q3 2020 | 2020-09-30 | $2.00B | $3.47B | — |
| Q2 2020 | 2020-06-30 | −$2.98B | −$5.41B | — |
| Q1 2020 | 2020-03-31 | $2.40B | $165.0M | +7.38% |
| Q4 2019 | 2019-12-31 | $1.09B | −$51.0M | −4.46% |
| Q3 2019 | 2019-09-30 | −$1.47B | −$4.10B | — |
| Q2 2019 | 2019-06-30 | $2.43B | $150.0M | +6.58% |
| Q1 2019 | 2019-03-31 | $2.24B | $84.0M | +3.90% |
| Q4 2018 | 2018-12-31 | $1.14B | −$1.15B | −50.07% |
| Q3 2018 | 2018-09-30 | $2.62B | −$1.19B | −31.19% |
| Q2 2018 | 2018-06-30 | $2.28B | −$1.97B | −46.40% |
| Q1 2018 | 2018-03-31 | $2.15B | −$1.61B | −42.85% |
| Q4 2017 | 2017-12-31 | $2.29B | −$1.75B | −43.36% |
| Q3 2017 | 2017-09-30 | $3.81B | −$587.0M | −13.34% |
| Q2 2017 | 2017-06-30 | $4.25B | −$284.0M | −6.26% |
| Q1 2017 | 2017-03-31 | $3.77B | −$884.0M | −19.01% |
| Q4 2016 | 2016-12-31 | $4.04B | −$1.58B | −28.04% |
| Q3 2016 | 2016-09-30 | $4.40B | −$1.19B | −21.24% |
| Q2 2016 | 2016-06-30 | $4.54B | −$1.08B | −19.20% |
| Q1 2016 | 2016-03-31 | $4.65B | −$720.0M | −13.41% |
| Q4 2015 | 2015-12-31 | $5.62B | $1.29B | +29.82% |
| Q3 2015 | 2015-09-30 | $5.58B | $2.10B | +60.49% |
| Q2 2015 | 2015-06-30 | $5.62B | $1.20B | +27.29% |
| Q1 2015 | 2015-03-31 | $5.37B | $2.33B | +76.50% |
| Q4 2014 | 2014-12-31 | $4.33B | $3.13B | +261.72% |
| Q3 2014 | 2014-09-30 | $3.48B | $2.33B | +203.17% |
| Q2 2014 | 2014-06-30 | $4.41B | $3.26B | +282.38% |
| Q1 2014 | 2014-03-31 | $3.04B | $2.02B | +196.80% |
| Q4 2013 | 2013-12-31 | $1.20B | $90.2M | +8.15% |
| Q3 2013 | 2013-09-30 | $1.15B | $103.9M | +9.96% |
| Q2 2013 | 2013-06-30 | $1.15B | $94.7M | +8.95% |
| Q1 2013 | 2013-03-31 | $1.03B | $225.1M | +28.13% |
| Q4 2012 | 2012-12-31 | $1.11B | $239.3M | +27.59% |
| Q3 2012 | 2012-09-30 | $1.04B | $40.2M | +4.01% |
| Q2 2012 | 2012-06-30 | $1.06B | $42.4M | +4.17% |
| Q1 2012 | 2012-03-31 | $800.2M | −$101.8M | −11.28% |
| Q4 2011 | 2011-12-31 | $867.5M | $38.1M | +4.59% |
| Q3 2011 | 2011-09-30 | $1.00B | $24.6M | +2.51% |
| Q2 2011 | 2011-06-30 | $1.02B | $24.1M | +2.43% |
| Q1 2011 | 2011-03-31 | $902.0M | −$259.2M | −22.32% |
| Q4 2010 | 2010-12-31 | $829.4M | −$236.1M | −22.16% |
| Q3 2010 | 2010-09-30 | $979.1M | $84.7M | +9.47% |
| Q2 2010 | 2010-06-30 | $992.6M | $231.6M | +30.43% |
| Q1 2010 | 2010-03-31 | $1.16B | $352.8M | +43.65% |
| Q4 2009 | 2009-12-31 | $1.07B | — | — |
| Q3 2009 | 2009-09-30 | $894.4M | $200.6M | +28.91% |
| Q2 2009 | 2009-06-30 | $761.1M | $155.5M | +25.69% |
| Q1 2009 | 2009-03-31 | $808.3M | — | — |
| Q3 2008 | 2008-09-30 | $693.8M | — | — |
| Q2 2008 | 2008-06-30 | $605.5M | — | — |
Gilead Sciences operating income trends
Over the last five fiscal years, Gilead Sciences's operating income increased from $4.07B to $10.02B, a change of $5.95B. The latest reported quarter, Q2 2026, shows −$10.39B.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gilead Sciences source filings ↗Community posts
Gilead raises its sales outlook but projects a deeper acquisition-driven annual loss
Gilead ($GILD) increased its 2026 product-sales forecast to $31.0–$31.3 billion from $30.1–$30.4 billion after third-quarter 2026 product revenue rose 13% to $8.3 billion. HIV sales grew 18% to $6.2 billion, supported by demand, pricing and ...
Gilead agrees $1.275 billion purchase of PepStar's oral inflammation program
Gilead ($GILD) agreed to acquire worldwide rights to PepStar's investigational oral IL-23 receptor inhibitor program, led by HCXT-2001. The agreement calls for $1.275 billion in upfront cash consideration payable at closing, subject to cust ...
